Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression alternations in liraglutide treated rats cardiac muscle

ABSTRACT: Diabetic rats changes gene exprssion in liraglutide treated rats cardiac muscle

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE102194 | GEO | 2018/03/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression alternations in liraglutide treated rats cardiac muscle

Project description:Expression alternations in liraglutide treated rats cardiac muscle

| PRJNA397128 | ENA

miRNA expression alterations in liraglutide treated rats arota

Project description:liraglutide may distrub miRNA expression in diabetic rats arota

2019-02-11 | GSE102198 | GEO

Gene expression alternations in vildagliptin treated rats arota

Project description:Diabetic rats changes gene exprssion in vildagliptin treated rats arota

2018-04-26 | GSE102196 | GEO

Gene expression alternations in Qishen Yiqi Dripping Pill-treated rats kidney

Project description:Diabetic rats changes gene exprssion in Qishen Yiqi Dripping Pill-treated rats kidney Diabetic nephropathy (DN) is a severe microvascular complication of diabetes. Qishen Yiqi Dripping Pill (QYDP) has been reported to be a renal protective drug. However, the mechanisms remain not certain. This study was performed to investigate the mechanisms of the extract. In this study, Sprague Dawley SD rats were fed with a high-fat diet, and injected with streptozotocin (STZ) to generate a diabetic model. Diabetic rats were administered QYDP.

2021-02-01 | GSE134072 | GEO

Gene expression alternations in Shenqi Jiangtang Granule-treated rats kidney

Project description:Diabetic rats changes gene exprssion in Shenqi Jiangtang Granule-treated rats kidney Diabetic nephropathy (DN) is a major microvascular complication of diabetes. In addition to moderating hyperglycemia, Shenqi Jiangtang Granule (SJG) had a beneficial effect on kidney function in a clinical trial. However, the mechanism involved remains unclear. This study was conducted to identify the underlying molecular mechanisms. A diabetic rat model was generated by using a high-fat diet and streptozotocin (STZ) injection. Then, rats were given SJG at dosages of 800 mg/kg/d by gavage for 8 weeks.

2019-12-17 | GSE134071 | GEO

Expression alternations in liraglutide treated rats cardiac muscle

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-03-30 | GSE102200 | GEO

cardiac proteomics in obese rats

Project description:Cardiac proteome analysis of obese rats treated with mitoQ

2023-06-29 | PXD034955 | JPOST Repository

Liraglutide effect on STZ Mouse Kidney with diabetic nephropathy

Project description:The effect of liraglutide on the kidney proteome in the STZ mouse model compared to healthy and STZ diabetic control groups.

2019-01-18 | PXD003007 | Pride

Liraglutide inhibits osteoclastogenesis and improves bone loss by down-regulating Trem2 in female type 1 diabetic mice: findings from transcriptomics

Project description:Aims:We aimed to explore possible mechanisms of bone loss in T1D and clarify whether liraglutide have effects on bone quality of T1D mice using transcriptomics, . Methods:Female streptozotocin-induced diabetic C57BL/6J mice were randomly divided into 4 groups and received the following treatments daily for 8 weeks: saline as controls; insulin; liraglutide; liraglutide combined with insulin. These groups were also compared to non-STZ-treated normal glucose tolerance (NGT) group. Trunk blood and bone tissues were collected for analysis. Three tibia from each of the NGT, saline treated and liraglutide treated group were randomly selected for transcriptomics. Results:Compared with NGT mice,saline treated T1D mice manifested markedly hyperglycemia and weight loss, and micro-CT revealed significantly lower bone mineral density(BMD) and deficient microarchitectures in tibias.8 weeks’ treatment with liraglutide alone or combined with insulin rescued the decreased BMD and partly corrected compromised trabecular microarchitectures. Transcriptomics analysis showed there were 789 differentially expressed genes mainly mapped to osteoclastogenesis and inflammation pathways.RT-qPCR verified gene expression of Trem2, Nfatc1, Trap and Ctsk were significantly increased in tibia of T1D compared to that in NGT group. Liraglutide treatment alone or combined with insulin could effectively suppress osteoclastogenesis by down-regulating gene expression of Trem2, Nfatc1, Ctsk and Trap.

2021-11-21 | GSE189112 | GEO

Single cell transcriptome profiling of kidney cell populations and the effect of liraglutide in diabetes

Project description:While incretin-based therapies are known to improve glucose control in diabetes, growing evidence suggests a glucose-independent mechanism in protection against kidney disease. To further investigate incretin effects in kidney, we examined long-term therapy with liraglutide, a Glucagon-like peptide 1 receptor (GLP1R) agonist, in diabetic (Ins2Akita) and control mice and profiled renal cell transcriptomes using single-cell sequencing.

2024-05-02 | GSE220045 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data